JP2017503481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503481A5 JP2017503481A5 JP2016536527A JP2016536527A JP2017503481A5 JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5 JP 2016536527 A JP2016536527 A JP 2016536527A JP 2016536527 A JP2016536527 A JP 2016536527A JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- lenalidomide
- patient
- pharmaceutically acceptable
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 44
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 44
- 108090000623 proteins and genes Proteins 0.000 claims 36
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 32
- 229960004942 lenalidomide Drugs 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 29
- 230000014509 gene expression Effects 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 28
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 239000012472 biological sample Substances 0.000 claims 25
- 239000000523 sample Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 20
- 230000035945 sensitivity Effects 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 8
- 210000004443 dendritic cell Anatomy 0.000 claims 5
- 210000004180 plasmocyte Anatomy 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| US61/913,046 | 2013-12-06 | ||
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503481A JP2017503481A (ja) | 2017-02-02 |
| JP2017503481A5 true JP2017503481A5 (enExample) | 2018-01-18 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536527A Pending JP2017503481A (ja) | 2013-12-06 | 2014-12-05 | 血液癌を治療する方法及び免疫調節療法に対する臨床的感受性の予測因子としてのバイオマーカーの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (enExample) |
| EP (1) | EP3077547A4 (enExample) |
| JP (1) | JP2017503481A (enExample) |
| KR (1) | KR20160090390A (enExample) |
| AU (1) | AU2014360316A1 (enExample) |
| BR (1) | BR112016012792A2 (enExample) |
| CA (1) | CA2932266A1 (enExample) |
| EA (1) | EA201691143A1 (enExample) |
| IL (1) | IL245936A0 (enExample) |
| MX (1) | MX2016007179A (enExample) |
| PH (1) | PH12016501023A1 (enExample) |
| WO (1) | WO2015085160A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| EP3996039A1 (en) * | 2014-10-17 | 2022-05-11 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| US10338077B2 (en) | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| US11459613B2 (en) | 2015-09-11 | 2022-10-04 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of Cereblon |
| JP2018529344A (ja) * | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| US10648983B2 (en) | 2016-01-08 | 2020-05-12 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| JP7357921B2 (ja) * | 2017-09-29 | 2023-10-10 | 国立大学法人九州大学 | びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット |
| AU2020372333A1 (en) * | 2019-10-21 | 2022-04-28 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158740A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| EP2544687A1 (en) * | 2010-03-12 | 2013-01-16 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
-
2014
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
-
2016
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503481A5 (enExample) | ||
| JP2016500110A5 (enExample) | ||
| Rojas et al. | Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment | |
| Tan et al. | Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker | |
| Tuncbilek et al. | Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-d-ribofuranosyl) purine derivatives, which lead to senescence-induced cell death in liver cancer cells | |
| BR112017025254A2 (pt) | ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento? | |
| JO3681B1 (ar) | استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr | |
| HRP20180002T1 (hr) | Kompozicije i postupci za liječenje karcinoma | |
| JP2016536303A5 (enExample) | ||
| Jang et al. | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma | |
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| JP2016501013A5 (enExample) | ||
| Tang et al. | Epidemiologic characteristics, prognostic factors, and treatment outcomes in primary central nervous system lymphoma: a SEER-based study | |
| Kim et al. | OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib | |
| Yu et al. | A meta‐analysis: micro RNA s’ prognostic function in patients with nonsmall cell lung cancer | |
| JP2016510591A5 (enExample) | ||
| Wang et al. | Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions. | |
| MX2016012718A (es) | Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. | |
| An et al. | Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy | |
| Forsythe et al. | Using organoid models to predict chemotherapy efficacy: the future of precision oncology? | |
| Bialopiotrowicz et al. | Microenvironment-induced expression of PIM kinases supports chronic lymphocytic leukemia cells survival and promotes CXCR4-mTOR pathway dependent migration | |
| WO2023023592A1 (en) | Repurposing drugs for non-small cell lung cancer | |
| Li et al. | Expression of high mobility group box-1 in colorectal cancer and its clinical significance | |
| Lee et al. | Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma | |
| Keats et al. | Interim analysis of the MMRF CoMMpass study: comprehensive characterization of multiple myeloma patients at diagnosis reveals distinct molecular subtypes and clinical outcomes |